Navigation Links
Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
Date:6/2/2008

patient instruction, and insulin dose adjustments are critical elements for reducing this risk. This information is highlighted in a boxed warning in the SYMLIN prescribing information for healthcare professionals and in a medication guide for patients, which will be distributed by pharmacists.

Other adverse events commonly observed with SYMLIN when co-administered with insulin were mostly gastrointestinal in nature, including nausea, which was the most frequently reported. The incidence of nausea was higher at the beginning of SYMLIN treatment and decreased with time in most patients. The incidence and severity of nausea are reduced when SYMLIN is gradually increased to the recommended doses.

About BYETTA

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is an add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control, low incidence of hypoglycemia when used with metformin or a thiazolidinedione, and progressive weight loss. BYETTA was approved in April 2005 and has been used by approximately one million patients since its introduction. For full prescribing information, visit http://www.BYETTA.com.

Important Safety Information for BYETTA

BYETTA improves glucose (blood sugar) control in adults with type 2 diabetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommend
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
2. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
3. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
4. Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
5. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
6. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
7. Amylin Pharmaceuticals to Webcast First Quarter Results
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
10. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
11. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... ... August 05, 2015 , ... MTI-GlobalStem, ... the launch of an updated corporate identity, including new company name, logo and ... in 2009. The company moved into a new, joint facility in 2014 to ...
(Date:8/4/2015)... (NYSE: BIOA ), a leader in renewable materials ... June 30, 2015. Highlights included: , The Sarnia plant ... final cost of the Sarnia plant is projected to ... end of the estimate communicated at the onset of ... company announced commercial collaborations in two targeted industry segments; ...
(Date:8/4/2015)... According to a new ... Cardiac Biomarker - Market Opportunities, and Forecast, 2014-2020", ... revenue of $2,085.9 million by 2020, registering a ... Troponins (T, I) would continue to dominate the ... sensitivity and specificity.      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:8/4/2015)... ... August 04, 2015 , ... RPS Diagnostics (RPS®) – a ... that Robert A. Gregg, PhD, has joined RPS as Senior Vice President of ... experience and remarkable achievements in the medical device and diagnostics industries. , “Bob ...
Breaking Biology Technology:MTI-GlobalStem Announces Updated Company Identity and Website 2MTI-GlobalStem Announces Updated Company Identity and Website 3BioAmber Reports Second Quarter 2015 Financial Results 2BioAmber Reports Second Quarter 2015 Financial Results 3BioAmber Reports Second Quarter 2015 Financial Results 4BioAmber Reports Second Quarter 2015 Financial Results 5BioAmber Reports Second Quarter 2015 Financial Results 6BioAmber Reports Second Quarter 2015 Financial Results 7BioAmber Reports Second Quarter 2015 Financial Results 8BioAmber Reports Second Quarter 2015 Financial Results 9BioAmber Reports Second Quarter 2015 Financial Results 10BioAmber Reports Second Quarter 2015 Financial Results 11BioAmber Reports Second Quarter 2015 Financial Results 12Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3
... Dec. 17 Phosphagenics,Limited ("Phosphagenics") (ASX: POH, AIM: ... Phase 1 clinical trial that showed its,delivery technology, ... without causing disruption or irritation of any kind., ... the first company to,commercialize a sustained release oxycodone ...
... Provide Unprecedented Visibility into, Enterprise-Wide Spend Management Practices; Supplier Enablement Capability ... Spending with Preferred ... ... leader,in helping academic and research-centric organizations realize the,potential of strategic procurement, ...
... Dec. 17 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... clinical trial which is designed to support an ... for the treatment of patients,with NYHA Class II ... diligently on the ACCLAIM-II study,including the establishment of ...
Cached Biology Technology:Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 2Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 3AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services 2AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services 3Vasogen Provides an Update on ACCLAIM-II Preparations 2Vasogen Provides an Update on ACCLAIM-II Preparations 3Vasogen Provides an Update on ACCLAIM-II Preparations 4
(Date:7/31/2015)... juillet 2015 La 10e Conférence internationale ... organisée par le BGI du 22 au 25 ... en Chine. La conférence célèbre son ... 2006, l,ICG est devenue l,une des réunions annuelles ... « omiques » et c,est aussi la plus dynamique, la ...
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, featuring FPC,s ... in 2015 that relate to sales of FPC1025 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... China and we are proud that ... Axon , its first smartphone ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... a common chemotherapy agent, researchers at UCLA's Jonsson Cancer ... found a way to move an important biomarker expressed ... in a cell ?where it could not be accessed ... The discovery, outlined in the cover article of May ...
... ended a decade-long controversy over the process by which ... ?the fragrant substances plants produce and which are often ... and other animals were incapable of making these substances. ... control pheromone production," said Gary Blomquist, professor and chair ...
... University of North Carolina at Chapel Hill's newest "library" ... book lover, but it eventually will please thousands of ... it will undoubtedly contribute to improving crops that humans ... say. , Named Phytome, the unique library is a ...
Cached Biology News:UCLA cancer researchers shake loose hidden biomarker 2Researchers discover key gene involved in bark beetle pheromone production 2Unique library of plant genes germinates, takes root at UNC 2
MpV17 transgene, murine homolog, glomerulosclerosis...
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: